TRZ is a humanized monoclonal antibody that disrupts ErbB2 (HER2/neu) signaling, and although its use has revolutionized the care of HER2+ breast cancer, it can result in clinically significant cardiotoxicity. The gene discussed is ERBB2; the disease is breast carcinoma.